 |
市场调查报告书
商品编码
1890919
血脂异常症治疗市场：依适应症、药物类别、给药途径、年龄层、性别、通路和地区划分Lipid Disorder Treatment Market, By Indication, By Drug Class, By Route of Administration, By Age Group, By Gender, By Distribution Channel, By Geography |
||||||
预计到 2025 年，血脂异常症治疗市场价值将达到 301.4 亿美元，到 2032 年将达到 513.2 亿美元，2025 年至 2032 年的复合年增长率为 7.9%。
| 报告内容 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2024 | 2025年市场规模： | 301.4亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2025年至2032年 |
| 预测期（2025-2032年）复合年增长率： | 7.90% | 2032 年的预测值： | 513.2亿美元 |
全球血脂异常症治疗市场是医药和医疗保健产业的重要组成部分，旨在应对全球日益普遍的血脂异常症及其相关心血管併发症。血脂异常的特征是血脂异常症，已成为影响全球数百万人的重大公共卫生问题。
高胆固醇症、高三酸甘油脂血症和混合型血脂异常等疾病是心血管疾病的主要危险因素，而心血管疾病是全球主要的死亡原因之一。治疗方法包括多种治疗方法，例如他汀类药物、贝特类药物、胆汁酸螯合剂、PCSK9抑制剂以及针对不同脂质代谢途径的新兴创新治疗方法。
推动这一市场成长的因素包括：人们对心血管健康的日益关注、肥胖和糖尿病盛行率的上升、久坐的生活方式以及已开发国家和开发中国家人口的老化。此外，持续的研发活动不断推出疗效和安全性更高的创新疗法，促进了市场扩张，并为医疗专业人员提供了多种治疗选择，以有效控制血脂异常症。
市场动态
全球血脂异常症治疗市场的主要驱动力是心血管和代谢疾病盛行率的不断上升，其中肥胖、糖尿病和高血压是全球血脂异常症的主要诱发因素。老年人口的成长，尤其是在已开发地区，正显着加速市场成长，因为与老龄化相关的脂质代谢变化会增加血脂异常症的风险。
药物研发领域的技术进步，包括PCSK9抑制剂和联合治疗的出现，彻底改变了治疗模式，为难治性高高胆固醇症患者拓展了治疗选择。不断上涨的医疗成本、日益提高的诊断能力以及人们对心血管疾病预防保健意识的增强，正推动市场进一步扩张。然而，该市场也面临着许多限制因素，例如，随着重磅他汀类药物专利到期，学名药的竞争和价格下降；新药认证的严格监管要求；以及人们对某些降脂药物长期安全性的担忧。
此外，高昂的治疗费用，尤其是像PCSK9抑制剂这样的新型治疗方法，限制了价格敏感市场的可及性，并造成了报销方面的挑战。儘管有这些限制，发展中经济体尚未开发的市场仍蕴藏着巨大的机会，这些经济体医疗基础设施的改善和中产阶级人口的成长正在推动需求。
个人化医疗、生物标记指导治疗方法和新型药物递送方法的发展蕴藏着盈利的商机。此外，人们越来越关注联合治疗以实现最佳血脂靶点，以及治疗罕见遗传性血脂异常症的潜力，这些都为投资创新疗法的製药公司提供了显着的成长前景。
本次调查的主要特点
- 本报告对全球血脂异常症治疗市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和復合年增长率百分比。
- 我们将重点介绍各个细分市场的潜在商机，并说明该市场具有吸引力的投资提案矩阵。
- 该研究还提供了有关市场驱动因素、阻碍因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本报告根据以下参数对全球血脂异常症治疗市场的主要企业进行了分析：公司概况、产品系列、主要特征、财务绩效和策略。
- 本报告的研究结果将使负责人和经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 这份全球血脂异常症治疗市场报告的目标受众包括该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 相关人员可以透过分析全球血脂异常症治疗市场所使用的各种策略矩阵轻鬆做出决策。
目录
第一章 研究目标与前提条件
- 调查目的
- 先决条件
- 简称
第二章 市场范围
- 报告概述
- 市场定义和范围
- 执行摘要
第三章 市场动态、监理及趋势分析
- 市场动态
- 司机
- 抑制因素
- 机会
- 影响分析
- 重大进展
- 法规环境
- 产品上市及核准
- PEST分析
- 波特分析
- 併购趋势
- 产业趋势
4. 2020-2032年全球血脂异常症治疗市场（依适应症划分）
- 高胆固醇症
- 高三酸甘油脂血症
- 混合型血脂异常
- 动脉粥状硬化性心血管疾病（ASCVD）
- 遗传性脂蛋白脂肪酶缺乏症
- 其他（遗传性转甲状腺素蛋白介导的类淀粉沉积症）
5. 2020-2032年全球血脂异常症治疗市场（依药物类别划分）
- 他汀类药物
- PCSK9抑制剂
- 胆汁酸螯合剂
- 胆固醇吸收抑制剂
- 贝特类药物
- 烟碱酸（维生素B3）
- Omega-3脂肪酸
- 联合治疗
- 其他后期药物
6. 2020-2032年全球血脂异常症药物市场（依类型划分）
- 非专利的
- 品牌
7. 2020-2032年全球血脂异常症药物市场（依给药途径划分）
- 口服
- 肠外
8. 2020-2032年全球血脂异常症治疗市场（依年龄层划分）
- 成人
- 儿童
- 老年人
9. 2020-2032年全球血脂异常症治疗市场（依性别划分）
- 男性
- 女士
10. 2020-2032年全球血脂异常症治疗市场（依通路划分）
- 零售药房
- 网路药房
- 医院药房
第十一章 2020-2032年全球血脂异常症治疗市场（按地区划分）
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十二章 竞争格局
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Novartis
- Merck &Co.
- Pfizer
- AstraZeneca
- Daiichi Sankyo
- Kowa Pharmaceuticals America
- Esperion Therapeutics
- Amarin Corporation
- Chiesi Global Rare Diseases
- AbbVie
- Viatris
- Teva Pharmaceutical Industries
第十三章 分析师建议
- 机会
- 分析师观点
- Coherent Opportunity Map
第十四章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Lipid Disorder Treatment Market is estimated to be valued at USD 30.14 Bn in 2025 and is expected to reach USD 51.32 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 30.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.90% | 2032 Value Projection: | USD 51.32 Bn |
The global lipid disorder treatment market represents a critical segment within the pharmaceutical and healthcare industry, addressing the growing prevalence of dyslipidemia and associated cardiovascular complications worldwide. Lipid disorders, characterized by abnormal levels of cholesterol, triglycerides, and other lipoproteins in the blood, have emerged as a significant public health concern affecting millions of individuals globally.
Conditions, including hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia, are primary risk factors for cardiovascular diseases, which remain the leading cause of mortality worldwide. The treatment landscape encompasses various therapeutic approaches, including statins, fibrates, bile acid sequestrants, PCSK9 inhibitors, and emerging novel therapies that target different pathways in lipid metabolism.
The market is driven by increasing awareness of cardiovascular health, rising prevalence of obesity and diabetes, sedentary lifestyles, and aging populations across developed and developing nations. Additionally, continuous research and development activities have led to the introduction of innovative treatment modalities with improved efficacy and safety profiles, contributing to market expansion and providing healthcare professionals with diverse therapeutic options to manage lipid disorders effectively.
Market Dynamics
The global lipid disorder treatment market is primarily driven by the escalating prevalence of cardiovascular diseases and metabolic disorders, with obesity, diabetes, and hypertension serving as key contributing factors to dyslipidemia worldwide. The growing geriatric population, particularly in developed regions, significantly amplifies market growth as age-related lipid metabolism changes increase susceptibility to lipid disorders.
Technological advancements in drug development, including the emergence of PCSK9 inhibitors and combination therapies, have revolutionized treatment paradigms and expanded therapeutic options for patients with refractory hypercholesterolemia. Increasing healthcare expenditure, improved diagnostic capabilities, and rising awareness about preventive cardiovascular care further propel market expansion. However, the market faces substantial restraints including patent expirations of blockbuster statin drugs leading to generic competition and price erosion, stringent regulatory requirements for new drug approvals, and concerns regarding long-term safety profiles of certain lipid-lowering medications.
Additionally, high treatment costs, particularly for novel therapies like PCSK9 inhibitors, limit accessibility in price-sensitive markets and create reimbursement challenges. Despite these constraints, significant opportunities emerge from untapped markets in developing economies where healthcare infrastructure improvements and growing middle-class populations drive demand.
The development of personalized medicine approaches, biomarker-guided therapies, and novel drug delivery systems present lucrative opportunities. Furthermore, increasing focus on combination therapies to achieve optimal lipid targets and the potential for treating rare genetic lipid disorders offer substantial growth prospects for pharmaceutical companies investing in innovative therapeutic solutions.
Key Features of the Study
- This report provides in-depth analysis of the global lipid disorder treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lipid disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen, Sanofi, Regeneron Pharmaceuticals, Novartis, Merck and Co., Pfizer, AstraZeneca, Daiichi Sankyo, Kowa Pharmaceuticals America, Esperion Therapeutics, Amarin Corporation, Chiesi Global Rare Diseases, AbbVie, Viatris, and Teva Pharmaceutical Industries
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lipid disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lipid disorder treatment market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Hypercholesterolemia
- Primary Hypercholesterolemia
- Familial Hypercholesterolemia
- Hypertriglyceridemia
- Mixed Dyslipidemia
- Elevated LDL-C and Triglycerides
- Low HDL-C with Elevated LDL-C
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Familial Lipoprotein Lipase Deficiency
- Others (Hereditary Transthyretin-Mediated Amyloidosis)
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Statins
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Others (Pravastatin, etc.)
- PCSK9 Inhibitors
- Alirocumab
- Evolocumab
- Others (Inclisiran, etc.)
- Bile Acid Sequestrants
- Colesevelam
- Colestipol
- Others (Cholestyramine, etc.)
- Cholesterol Absorption Inhibitors
- Ezetimibe
- Bempedoic Acid
- Fibrates
- Fenofibrate
- Gemfibrozil
- Niacin (Vitamin B3)
- Nicotinic Acid
- Omega-3 Fatty Acids
- Icosapent ethyl (Vascepa)
- Omega-3-acid ethyl esters (Lovaza)
- Combination Therapies
- Ezetimibe/Statin Combinations
- Other Late Phase Drugs
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic
- Brand
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults
- Pediatric
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amgen
- Sanofi
- Regeneron Pharmaceuticals
- Novartis
- Merck & Co.
- Pfizer
- AstraZeneca
- Daiichi Sankyo
- Kowa Pharmaceuticals America
- Esperion Therapeutics
- Amarin Corporation
- Chiesi Global Rare Diseases
- AbbVie
- Viatris
- Teva Pharmaceutical Industries
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Lipid Disorder Treatment Market, By Indication
- Global Lipid Disorder Treatment Market, By Drug Class
- Global Lipid Disorder Treatment Market, By Type
- Global Lipid Disorder Treatment Market, By Route of Administration
- Global Lipid Disorder Treatment Market, By Age Group
- Global Lipid Disorder Treatment Market, By Gender
- Global Lipid Disorder Treatment Market, By Distribution Channel
- Global Lipid Disorder Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Lipid Disorder Treatment Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hypercholesterolemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Hypercholesterolemia
- Familial Hypercholesterolemia
- Hypertriglyceridemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Dyslipidemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Elevated LDL-C and Triglycerides
- Low HDL-C with Elevated LDL-C
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Familial Lipoprotein Lipase Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Hereditary Transthyretin-Mediated Amyloidosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Lipid Disorder Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Atorvastatin
- Rosuvastatin
- Simvastatin
- Others (Pravastatin, etc.)
- PCSK9 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alirocumab
- Evolocumab
- Others (Inclisiran, etc.)
- Bile Acid Sequestrants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Colesevelam
- Colestipol
- Others (Cholestyramine, etc.)
- Cholesterol Absorption Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ezetimibe
- Bempedoic Acid
- Fibrates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fenofibrate
- Gemfibrozil
- Niacin (Vitamin B3)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nicotinic Acid
- Omega-3 Fatty Acids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Icosapent ethyl (Vascepa)
- Omega-3-acid ethyl esters (Lovaza)
- Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ezetimibe/Statin Combinations
- Other Late Phase Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Lipid Disorder Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Lipid Disorder Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Lipid Disorder Treatment Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Lipid Disorder Treatment Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Lipid Disorder Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Lipid Disorder Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kowa Pharmaceuticals America
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Esperion Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amarin Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chiesi Global Rare Diseases
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
